Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
PetVivo Holdings, Inc. (warrants trading as PETVW alongside common stock PETV on OTCQX) generates a steady flow of news around its role as an emerging biomedical device company in the companion animal and equine markets. Company releases highlight developments in its veterinary medical devices and therapeutics, AI-powered platforms, distribution partnerships and corporate governance, providing context for investors and veterinary professionals following the PETVW warrants.
Recent news has focused on SPRYNG® with OsteoCushion® technology and PrecisePRP®, PetVivo’s lead products for managing joint-related conditions and musculoskeletal restoration in cats, dogs and horses. Articles describe clinical adoption, distributor expansion, continuing education initiatives for veterinarians and collaborations with equine-focused partners that integrate these products into care protocols.
Another major news theme is the company’s move into artificial intelligence through PetVivo AI, Inc. and the PetVivo.ai platform. Press releases detail an exclusive 10-year licensing agreement for the Agentic Pet AI framework, beta testing results, and the launch of a two-sided ecosystem that uses specialized AI agents to reduce veterinary client acquisition costs and connect practices with engaged pet parents. Additional coverage discusses technical validation of the framework via a published whitepaper and the release of a video explainer for PetVivo.ai.
News items also cover earnings announcements, conference calls and investor presentations, as well as board changes such as the appointment of an independent director. For anyone tracking PETVW, this news page offers a centralized view of PetVivo’s operational updates, product milestones, AI initiatives and strategic partnerships. Investors and observers can review these articles to understand how the company’s veterinary devices, regenerative products and AI platforms are being positioned in the animal health market.
PetVivo (OTCQX: PETV) reported fiscal Q3 and first nine months results ended Dec 31, 2025 and announced multiple commercial and R&D milestones. Key developments include an exclusive 10-year white-label license for AgenticPet AI, launch of PetVivo.ai beta, VGP distribution commitment to 7,300 clinics, Health Canada acknowledgement, and progress on biomaterials R&D and clinical pilots.
Management highlighted PetVivo.ai’s demonstrated 50%–90% reduction in veterinary customer acquisition cost, 80%–90% gross margins on the SaaS offering, and near-term commercial expansion into Canada and Europe.
PetVivo (OTCQX: PETV) retracted and replaced its Feb 9, 2026 press release and set a fiscal third quarter 2026 conference call for Tuesday, February 17, 2026 at 5:00 p.m. ET. Results for the quarter ended December 31, 2025 will be released in a prior press release before the call.
Management will present and take questions. Dial-in, conference ID, passcode, and a live webcast with replay are provided; replay will also be posted in the Investors section at petvivo.com/investors.
PetVivo (OTCQX: PETV) will host its Fiscal Third Quarter 2026 conference call on Monday, February 16, 2026 at 5:00 p.m. ET to discuss results for the quarter ended December 31, 2025. A press release with financial results will be issued prior to the call.
Dial-in, conference ID, passcode, and a live webcast with replay will be available; replay also posted in the Investors section at petvivo.com/investors.
PetVivo Holdings (OTCQX: PETV) announced that Health Canada has formally acknowledged Spryng with OsteoCushion Technology as a veterinary medical device for use in Canada. This regulatory acknowledgement is presented as a milestone in the company’s global commercialization strategy. The company said Spryng is a veterinarian-administered intra-articular injectable to support joint health and manage lameness in companion animals and equine athletes. Commercial availability in Canada is not immediate; PetVivo cited distribution setup, Canadian-specific packaging and labeling, and other operational requirements and currently anticipates potential availability in Q2 2026. Spryng is already commercially available in the United States and via select international distributors.
PetVivo Holdings (OTCQX:PETV) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026 at The Borgata, Atlantic City.
CEO John Lai will deliver a company presentation and hold one-on-one investor meetings. The presentation will cover lead products Spryng (intra-articular ECM microparticle device with OsteoCushion technology) and PrecisePRP (off-the-shelf allogeneic, leucoreduced, freeze-dried PRP: 4 billion platelets per vial; 500,000 platelets/µL; <1500 WBC/µL). Investors may request a complimentary investor pass and contact info1@petvivo.com or visit petvivoanimalhealth.com and sprynghealth.com for more information.
PetVivo.ai (OTCQX: PETV / OTCID: PETVW) released a concise video explainer on Dec. 16, 2025 that replaces a traditional technical press release with a visual walkthrough. The video demonstrates PetVivo.ai's two-sided ecosystem connecting pet parents with veterinary practices and outlines the platform's 10 specialized AI agents (from Behavioral Scientists to Radiologists). The walkthrough shows user journeys for both pet parents and veterinarians and highlights the company's focus on clear, jargon-free communication. The explainer is available on YouTube and the company's website for investors and users to view.
PetVivo AI (OTCQX: PETV) launched PetVivo.ai, an AI SaaS platform for veterinary practices on Nov 25, 2025, after a 50-practice beta.
Key disclosed metrics: qualified leads $3 each, blended CAC $42.53 (beta), median 47 new clients per practice over six months, pricing $1,999/month, LTV/CAC 25:1, payback 1 month, and gross margins 80–90%. The company positions the product against a >$150B pet care market and 30,000 U.S. veterinary practices, citing potential SaaS multiple re‑rating if adoption scales.
PetVivo (OTCQX: PETV) launched PetVivo.ai on November 25, 2025, an AI platform the company says reduces veterinary customer acquisition costs to $42.53 (a 50–89% reduction versus typical $80–$400) and generates qualified leads for $3 each. The platform uses nine AI agents across discovery, campaign management, engagement, analytics, content, reputation, compliance, ROI optimization and integration.
Beta economics (50 practices) reported a median of 47 new clients over 6 months, $3 lead cost, 80–90% gross margins, 25:1 LTV/CAC, 1 month payback and a Professional price of $1,999/month. PetVivo projects $12M ARR (Year 1), $180M ARR (Year 3) and $360M ARR (Year 5) from target practice adoption.
PetVivo (OTCQX: PETV) announced publication of Digital Landia’s technical whitepaper validating the AgenticPet AI Framework that underpins PetVivo’s exclusive 10-year white-label licensing agreement signed October 2025.
The whitepaper describes a production-ready, multi-agent veterinary AI architecture with claimed 90–98% client acquisition cost reduction, five patent-pending innovations, enterprise features (end-to-end encryption, blockchain audit trails, HIPAA-aligned privacy), and 99.9% uptime design. PetVivo targets a Q1 2026 dual launch with B2C and B2B platforms and pre-launch registration opening January 2026.
PetVivo (OTCQX: PETV) reported fiscal Q2 2026 results for the quarter ended Sept 30, 2025, with revenues of $303,000, up 51% year-over-year and a record second fiscal quarter. Gross profit was $220,000 with a 72.6% gross margin. Operating loss widened to $2.1 million, and net loss increased to $3.0 million or $0.11 per share. Cash totaled $768,000 and total liabilities fell 79% to $1.1 million. Company cited product launches (PrecisePRP), distributor expansion, international entry, strategic partnerships, and AI and biomaterials collaborations as drivers of growth and future commercialization.